MedTrace Logo

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

NCT02036541 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2017-06-01

Study results available
· View outcomes & findings →

Summary

To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.

Conditions

Interventions

DEVICE

AqueSys XEN 45 Glaucoma Implant

Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • AqueSys, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard A Lewis, M.D. · Grutzmacher, Lewis & Sierra Surgical Eye Specialists

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-02-29
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02036541 on ClinicalTrials.gov